Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Simon Y. Graeber, Marcus Mall
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1185-1198
Closed Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
Jennifer L. Taylor‐Cousar, Paul D. Robinson, Michal Shteinberg, et al.
The Lancet (2023) Vol. 402, Iss. 10408, pp. 1171-1184
Closed Access | Times Cited: 64
Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis
Jennifer Loske, Mirjam Völler, Soeren Lukassen, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 209, Iss. 11, pp. 1338-1350
Open Access | Times Cited: 20
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment
Edith T. Zemanick, Bonnie W. Ramsey, Dorota Sands, et al.
Journal of Cystic Fibrosis (2025)
Open Access | Times Cited: 4
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy
Katherine B. Hisert, Susan E. Birket, John P. Clancy, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 10, pp. 916-931
Closed Access | Times Cited: 36
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Nicole Mayer-Hamblett, John P. Clancy, Raksha Jain, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 10, pp. 932-944
Open Access | Times Cited: 23
Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles
Mirjam Stahl, Martha Dohna, Simon Y. Graeber, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 3, pp. 2400004-2400004
Open Access | Times Cited: 15
Intestinal current measurement detects age-dependent differences in CFTR function in rectal epithelium
Simon Y. Graeber, Olaf Sommerburg, Yin Yu, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access | Times Cited: 1
Sex differences in airway disease: estrogen and airway surface liquid dynamics
Brian J. Harvey, Noel G. McElvaney
Biology of Sex Differences (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis
Isabelle Sermet‐Gaudelus, Sihem Benaboud, S. Bui, et al.
The Lancet (2024) Vol. 404, Iss. 10448, pp. 117-120
Closed Access | Times Cited: 7
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 7
Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis
Aricca D. Van Citters, Enid Aliaj, Jessica A. Alvarez, et al.
Journal of Cystic Fibrosis (2024)
Open Access | Times Cited: 6
Comprehensive Characterization of the Viscoelastic Properties of Bovine Submaxillary Mucin (BSM) Hydrogels and the Effect of Additives
Hanna Rulff, Robert F. Schmidt, Ling-Fang Wei, et al.
Biomacromolecules (2024) Vol. 25, Iss. 7, pp. 4014-4029
Open Access | Times Cited: 5
Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations
Aiswarya Premchandar, Ruiji Ming, Abed Baiad, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Highly branched poly β-amino ester/CpG-depleted CFTR plasmid nanoparticles for non-viral gene therapy in lung cystic fibrosis disease
Bei Qiu, Darío Manzanares, Yinghao Li, et al.
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 3, pp. 101292-101292
Open Access | Times Cited: 4
Plasmid Gene Therapy for Monogenic Disorders: Challenges and Perspectives
Marco Â. Luís, Miguel Ângelo Góes, Fátima Milhano Santos, et al.
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 104-104
Open Access
Critical Issues in the Management of CRMS/CFSPID Children: A National Real‐World Survey
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
Pediatric Pulmonology (2025) Vol. 60, Iss. 1
Open Access
Perinatal dysfunction of innate immunity in cystic fibrosis
Florian Jaudas, Florian Bartenschlager, Bachuki Shashikadze, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 782
Closed Access
Menadione as Antibiotic Adjuvant Against P. aeruginosa: Mechanism of Action, Efficacy and Safety
Kristela Shehu, Marc Schneider, Annette Kraegeloh
Antibiotics (2025) Vol. 14, Iss. 2, pp. 163-163
Open Access
Identifying novel therapeutic targets in cystic fibrosis through advanced single-cell transcriptomics analysis
George Sun, Yi‐Hui Zhou
Computers in Biology and Medicine (2025) Vol. 187, pp. 109748-109748
Open Access
Early, integrated palliative care for people with chronic respiratory disease: lessons learnt from lung cancer
Anne M. Walker, Donald R. Sullivan, Phan Nguyen, et al.
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
How Effectively Can Oxidative Stress and Inflammation Be Reversed When CFTR Function Is Pharmacologically Improved?
Valeria Rachela Villella, Alice Castaldo, Filippo Scialò, et al.
Antioxidants (2025) Vol. 14, Iss. 3, pp. 310-310
Open Access
Characteristics, Clinical Outcomes and Healthcare Utilization of Women with Cystic Fibrosis and their Live Newborns Delivered in the Hospital Setting
Stephanie Y. Cheng, Collette Raymond, Laurie Lambert, et al.
Journal of Obstetrics and Gynaecology Canada (2025), pp. 102809-102809
Closed Access
The Role of Yes‐Associated Protein in Inflammatory Diseases and Cancer
Bing Zhong, Jintao Du, Feng Liu, et al.
MedComm (2025) Vol. 6, Iss. 3
Open Access
Gene Therapy for Cystic Fibrosis: Overcoming Current Limitations and Future Directions
Nadir Ali Wassan, Asfia Qammar, Sarah Bürki, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 3, pp. 133-145
Closed Access
Page 1 - Next Page

Scroll to top